Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.
Goode EC, Clark AB, Mells GF, Srivastava B, Spiess K, Gelson WTH, Trivedi PJ, Lynch KD, Castren E, Vesterhus MN, Karlsen TH, Ji SG, Anderson CA, Thorburn D, Hudson M, Heneghan MA, Aldersley MA, Bathgate A, Sandford RN, Alexander GJ, Chapman RW, Walmsley M; UK-PSC Consortium; Hirschfield GM, Rushbrook SM. Goode EC, et al. Among authors: lynch kd. Hepatology. 2019 May;69(5):2120-2135. doi: 10.1002/hep.30479. Epub 2019 Mar 4. Hepatology. 2019. PMID: 30566748 Free PMC article.
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK; International Primary Sclerosing Cholangitis Study Group (IPSCSG); Levy C. Lynch KD, et al. Clin Gastroenterol Hepatol. 2020 Jan;18(1):179-187.e6. doi: 10.1016/j.cgh.2019.05.013. Epub 2019 May 14. Clin Gastroenterol Hepatol. 2020. PMID: 31100458 Free PMC article.
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis.
Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, Gerussi A, Saffioti F, Thorburn D, Nilsson E, Larsson G, Moum BA, van Munster KN, Ponsioen CY, Levy C, Nogueira NF, Bowlus CL, Gotlieb N, Shibolet O, Lynch KD, Chapman RW, Rupp C, Vesterhus M, Jørgensen KK, Rorsman F, Schramm C, Sabino J, Vermeire S, Zago A, Cazzagon N, Marschall HU, Ytting H, Ben Belkacem K, Chazouilleres O, Almer S; International PSC Study Group; Bergquist A. Hedin CRH, et al. Among authors: lynch kd. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2295-2304.e2. doi: 10.1016/j.cgh.2020.02.014. Epub 2020 Feb 15. Clin Gastroenterol Hepatol. 2020. PMID: 32068151
Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW, Lynch KD. Chapman RW, et al. Among authors: lynch kd. Br Med Bull. 2020 May 15;133(1):95-104. doi: 10.1093/bmb/ldaa006. Br Med Bull. 2020. PMID: 32282030 Review.
Epidemiology and outcomes of primary sclerosing cholangitis: an Australian multicentre retrospective cohort study.
Tan N, Ngu N, Worland T, Lee T, Abrahams T, Pandya K, Freeman E, Hannah N, Gazelakis K, Madden RG, Lynch KD, Valaydon Z, Sood S, Dev A, Bell S, Thompson A, Ding J, Nicoll AJ, Liu K, Gow P, Lubel J, Kemp W, Roberts SK, Majeed A; Melbourne Liver Group. Tan N, et al. Among authors: lynch kd. Hepatol Int. 2022 Oct;16(5):1094-1104. doi: 10.1007/s12072-022-10356-1. Epub 2022 Jun 3. Hepatol Int. 2022. PMID: 35657479 Free PMC article.
Surveillance MRI is associated with improved survival in patients with primary sclerosing cholangitis.
Tan N, Ngu N, Worland T, Lee T, Abrahams T, Freeman E, Hannah N, Gazelakis K, Madden RG, Lynch KD, Valaydon Z, Sood S, Dev A, Bell S, Thompson AJ, Ding JN, Nicoll AJ, Liu K, Pandya K, Gow P, Lubel J, Kemp W, Roberts SK, Majeed A. Tan N, et al. Among authors: lynch kd. Hepatol Commun. 2024 May 2;8(5):e0442. doi: 10.1097/HC9.0000000000000442. eCollection 2024 May 1. Hepatol Commun. 2024. PMID: 38696372 Free PMC article.
Global multi-stakeholder endorsement of the MAFLD definition.
Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Méndez-Sánchez N, et al. Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3. Lancet Gastroenterol Hepatol. 2022. PMID: 35248211 Free article. No abstract available.
38 results